Apexigen, a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, announced on March 18, 2022, that it had entered into a business combination agreement with Brookline Capital Acquisition Corp. (Nasdaq: BCAC), a special purpose acquisition company, pursuant to which Apexigen and Brookline Capital Acquisition Corp. would combine, with the former equityholders of both entities holding equity in the combined public company listed on the Nasdaq Stock Exchange. Apexigen has built a diversified pipeline of wholly owned and partnered assets leveraging its proprietary APXiMAB™ antibody discovery platform. The company’s lead asset, sotigalimab, is a potentially best-in-class and first-in-class CD40 agonist with unique epitope specificity and Fc receptor engagement for optimal therapeutic effect.

Apexigen will host an investor day to provide an overview of its antibody therapeutic pipeline and unique APXiMAB™ platform. The company will discuss sotigalimab’s Phase 2 development with a focus on melanoma, esophageal/GEJ and sarcoma indications, its positioning in the competitive landscape, key data to date and upcoming milestones. The company will also highlight its promising pre-clinical program APX601, an anti-TNFR2 antagonist antibody.

The investor day will feature presentations from Apexigen’s leadership team:

A live question and answer session will follow.